David R Strayer

Summary

Publications

  1. pmc A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31334. 2012
  2. doi request reprint Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies
    David R Strayer
    Department of Clinical Research, Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania 19103, USA
    J Interferon Cytokine Res 32:95-102. 2012

Detail Information

Publications2

  1. pmc A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31334. 2012
    ..The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C(12)U), in patients with debilitating CFS/ME...
  2. doi request reprint Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies
    David R Strayer
    Department of Clinical Research, Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania 19103, USA
    J Interferon Cytokine Res 32:95-102. 2012
    ..This result is consistent with serology studies showing that the NABs directed against r-IFNs do not effectively cross-react with n-IFNs...